9Harrigan EP, Miceli JJ. Anziano R A randomized evaluation of the effects of six antipsychotic agents on QTc in the absence and pres- ence of metabolic inhibition [ J ]. J Clin Psycho - pharmacol, 2004,24 ( 1 ) :62 - 69.
10Woodburne O. Levy. No significant QTc interval changes with high- dose ziprasidone: A Case Series[ J]. Journal of Psychiat- ric Practice,2004,10 (4) : 227 - 232.
5Broon S.Intramusular ziprasidone:moving beyond the conventional in the treatment of acute agitation in schizophrenia[J].J Clin Psychiatry,2003,64(Suppl 19):13.
6Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA, 1990, 264:2788-2790.
7Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry, 2001, 58:1161-1167.
8Mehtonen OP, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand, 1991, 84:58-64.
9Barnett AA. Safety concerns over antipsychotic drug sertindole. Lancet, 1996,348:256-257.
10Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ, 2001, 322:1207-1209.
2Zipursky RB,Menezes NM,Streiner DL.Risk of symptom recurrence with medication discontinuation in first-episodepsychosis:a systematic review[J].Schizophr Res,2014,152(2/3):408-414.
4Grootens KP,van Veelen NM,Peuskens J,et al.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder:results of an 8-week double-blind randomized controlled trial[J].Schizophr Bull,2011,37(2):352-361.
5Kiviniemi M,Suvisaari J,Isohanni M,et al.The characteristics and outcomes of hospitalised and outpatient-treated first-onset schizophrenia patients:a 5-year register linkage study[J].Int J Clin Pract,2013,67(11):1105-1112.
6Brunton L,Chabner B,Knollman B.Goodman and Gilman′s the pharmacological basis of therapeutics[M]12th ed.New York:Mc Graw Hill Professional,2010:417-455.
7Rybakowski JK,Vansteelandt K,Remlinger-Molenda A,et al.Extrapyramidal symptoms during treatment of first schizophrenia episode:results from EUFEST[J].Eur Neuropsychopharmacol,2014,24(9):1500-1505.
8Hasnain M,Vieweg WV.QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants:a comprehensive review[J].CNS Drugs,2014,28(10):887-920.
9Leucht S,Cipriani A,Spineli L,et al.Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia:a multiple-treatments meta-analysis[J].Lancet,2014,382(9896):951-962.
10Peuskens J,Pani L,Detraux J,et al.The effects of novel and newly approved antipsychotics on serum prolactin levels:a comprehensive review[J].CNS Drugs,2014,28(5):421-453.
